In the phase 3 LIBERTY study, the investigational monoclonal antibody, VYD2311, had significantly fewer adverse events than an mRNA COVID-19 vaccine, and it did not blunt vaccine-induced neutralizing titers when the two were given together.
|Articles|August 10, 2020
FDA Authorizes Sequencing-Based COVID-19 Test
Author(s)Grant M. Gallagher
The authorization is for an amplicon-based next-generation sequencing test from Helix.
Advertisement
Helix, a population genomics biotechnology company, has announced that it received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its COVID-19 NGS Test.
The test is an amplicon-based next-generation sequencing (NGS) test. It is used for the detection of nucleic acid from SARS-CoV-2 in upper respiratory specimens such as nasopharyngeal swabs, throat swabs, mid-turbinate nasal swabs, and anterior nasal swabs.
The test is multiplexed to enable a high number of samples to be sequenced on each instrument. The company hopes to raise its COVID-19 testing capacity to 100,000 tests per day.
“As one of the first next-generation sequencing tests authorized by the FDA, the Helix COVID-19 NGS Test will enable Helix to diversify and add redundancy to its existing supply chain for its PCR-based test, the Helix COVID-19 Test, also authorized for emergency use by the FDA,” Helix
"The authorization of our next-generation sequencing-based test is an important step forward in dramatically scaling our COVID-19 testing capacity while maintaining high sensitivity," said Marc Stapley, Helix President and CEO.
"Combined with the recent funding we announced from the NIH RADx program, we will quickly become one of the highest throughput COVID-19 testing labs in the country and help millions of Americans access much-needed tests with next-day turnaround time."
Advertisement
Related to this article
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
The 18-year old resident of the state suffered from acute disseminated encephalomyelitis. Pennsylvania numbers are surging with some of the highest state totals of measles cases in the country.
In its second disease cluster this summer, city officials are cleaning building towers in the South Bronx amidst an ongoing investigation and are rolling out measures to prevent future Legionnaires' cases.
The death was reported in Jefferson County where the coroner released a statement announcing it was in an unvaccinated woman.
FDA approved updated 2026-2027 COVID-19 vaccines from Pfizer-BioNTech, Moderna, and Novavax's partners, all reformulated to target the XFG variant, giving clinicians several options ahead of the fall respiratory virus season.
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.
The latest CDC numbers show a 6.2% increase of measles cases from week-to-week. Last week there was a 5.4% increase in cases showing a continuing steady increase dictated by ongoing outbreaks across the US.
Advertisement
Advertisement
Trending on Contagion Live
1
New IDSA/ESCMID S aureus Bacteremia Consensus Statements: a Risk Stratification Framework
2
Measles Update: October 2, 2026
3
FAQ: Rising Rabies Exposure Calls PEP Decisions Back in Focus
4
Clinical Considerations for Measles: Presentation, Treatment, and Hospitalization
5